甲状腺基因分类器正确预测细胞学不确定的良性结节:两项独立、多中心、前瞻性验证试验
两项独立、多种族、前瞻性多中心试验(TGCT-1/智利和TGCT-2/美国)验证10基因甲状腺分类器性能,共收集4061份细针穿刺样本,897份(22%)为不确定细胞学,270份有匹配手术病理和有效分类器评分。TGCT-1和TGCT-2的敏感性分别为90%和91%,特异性分别为89%和87%,阴性预测值分别为96%和94%,总体准确率均为89%。分类器可准确预测良性甲状腺结节,可接受监测作为诊断性手术的替代方案。
要点
- 10基因甲状腺分类器在两项独立、多种族、前瞻性多中心试验中验证,总体准确率均为89%。
- TGCT-1和TGCT-2的敏感性分别为90%和91%,特异性分别为89%和87%。
- 阴性预测值TGCT-1为96%、TGCT-2为94%,可准确预测良性结节以避免诊断性手术。
核心结论
- 分类器的临床验证在两项独立且种族多样的队列中表现出等效性能,可准确预测良性甲状腺结节,这些结节可接受监测作为诊断性手术的替代方案。
研究设计与样本
- 两项独立、种族多样、前瞻性多中心试验(TGCT-1/智利和TGCT-2/美国),从15家机构共收集4061份细针穿刺样本,其中897份(22%)为不确定细胞学,270份样本有匹配的手术病理和有效分类器评分。
主要发现
- TGCT-1中155个结节有41个恶性(癌症患病率26%),TGCT-2中115个结节有45个恶性(癌症患病率39%)。
- TGCT-1和TGCT-2的敏感性分别为90%[95%CI 77-97]和91%[95%CI 79-98]。
- TGCT-1和TGCT-2的特异性分别为89%[95%CI 82-94]和87%[95%CI 77-94]。
- TGCT-1和TGCT-2的阴性预测值分别为96%和94%,阳性预测值分别为74%和82%。
- 两队列总体准确率均为89%。
临床怎么用
- 原文结论指出,分类器可准确预测良性甲状腺结节,这些结节可接受监测作为诊断性手术的替代方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Although most thyroid nodules with indeterminate cytology are benign, in most of the world, surgery remains as the most frequent diagnostic approach. We have previously reported a 10-gene thyroid genetic classifier, which accurately predicts benign thyroid nodules. The assay is a prototype diagnostic kit suitable for reference laboratory testing and could potentially avoid unnecessary diagnostic surgery in patients with indeterminate thyroid cytology. Methods: Classifier performance was tested in two independent, ethnically diverse, prospective multicenter trials (TGCT-1/Chile and TGCT-2/USA). A total of 4061 fine-needle aspirations were collected from 15 institutions, of which 897 (22%) were called indeterminate. The clinical site was blind to the classifier score and the clinical laboratory blind to the pathology report. A matched surgical pathology and valid classifier score was available for 270 samples. Results: Cohorts showed significant differences, including (i) clinical site patient source (academic, 43% and 97% for TGCT-1 and -2, respectively); (ii) ethnic diversity, with a greater proportion of the Hispanic population (40% vs. 3%) for TGCT-1 and a greater proportion of African American (11% vs. 0%) and Asian (10% vs. 1%) populations for TGCT-2; and (iii) tumor size (mean of 1.7 and 2.5 cm for TGCT-1 and -2, respectively). Overall, there were no differences in the histopathological profile between cohorts. Forty-one of 155 and 45 of 115 nodules were malignant (cancer prevalence of 26% and 39% for TGCT-1 and -2, respectively). The classifier predicted 37 of 41 and 41 of 45 malignant nodules, yielding a sensitivity of 90% [95% confidence interval; CI 77-97] and 91% [95% CI 79-98] for TGCT-1 and -2, respectively. One hundred one of 114 and 61 of 70 nodules were correctly predicted as benign, yielding a specificity of 89% [95% CI 82-94] and 87% [95% CI 77-94], respectively. The negative predictive values for TGCT-1 and TGCT-2 were 96% and 94%, respectively, whereas the positive predictive values were 74% and 82%, respectively. The overall accuracy for both cohorts was 89%. Conclusions: Clinical validation of the classifier demonstrates equivalent performance in two independent and ethnically diverse cohorts, accurately predicting benign thyroid nodules that can undergo surveillance as an alternative to diagnostic surgery.
引用
- Zafereo M, McIver B, Vargas-Salas S, et al. A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials. Thyroid. 2020. PMID: 31910118. doi:10.1089/thy.2019.0490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。